scispace - formally typeset
S

Shailendra Saraf

Researcher at Pandit Ravishankar Shukla University

Publications -  77
Citations -  4821

Shailendra Saraf is an academic researcher from Pandit Ravishankar Shukla University. The author has contributed to research in topics: Drug delivery & Drug carrier. The author has an hindex of 29, co-authored 73 publications receiving 3696 citations. Previous affiliations of Shailendra Saraf include P.G. College.

Papers
More filters
Journal ArticleDOI

Limonoids: Overview of significant bioactive triterpenes distributed in plants kingdom

TL;DR: Limonoids are highly oxygenated, modified terpenoids with a prototypical structure either containing or derived from a precursor with a 4,4,8-trimethyl-17-furanylsteroid skeleton and their occurrence in the plant kingdom is confined to only plant families of order Rutales.
Journal ArticleDOI

Approaches for breaking the barriers of drug permeation through transdermal drug delivery.

TL;DR: This review focuses on the recent advancements in the TDDS which include iontophoresis, sonophores is, electroporation, microneedles, magnetophoreis, photomechanical waves and electron beam irradiation.
Journal ArticleDOI

Nanocarriers: Promising Vehicle for Bioactive Drugs

TL;DR: This review highlights the different types of nanoparticulate delivery systems employed for biotech drugs in the field of molecular medicine with a short overlook at its applications and the probable associated drawbacks.
Journal ArticleDOI

Cyclodextrin based novel drug delivery systems

TL;DR: Applications and comparative benefits of use of cyclodextrins (CDs) and their derivatives in the design of novel delivery systems like liposomes, microspheres, microcapsules, nanoparticles,cyclodextrin grafted cellulosic fabric, hydrogels, nanosponges, beads, nanogels/nanoassemblies and cyclodeXTrin-containing polymers are outlined.
Journal ArticleDOI

Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.

TL;DR: The latest works on various novel formulations loaded with various anti‐Alzheimer agents are discussed, which underlines the fact that majority of work related to the nose‐to‐brain delivery of anti‐AD drugs is limited only up to preclinical studies.